awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527D
Q42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527D
Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.
P2860
Q42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
87a142b115082b0e703f3f3f36e1d50ef133310d
P2860
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).